CTSO · XBRL financial data

Cytosorbents financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CTSO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of goods and services sold	11,052	11,047	13,956	13,957	10,469	10,572
Gross profit	29,952	32,118	20,733	22,392	25,126	26,491
Research and development	8,811	16,381	15,119	15,729	—	—
Selling, general and administrative	28,464	35,750	34,288	33,600	34,996	35,645
Total operating expenses	40,323	54,863	52,255	53,601	41,912	41,240
Operating income (loss)	(10,370)	(22,745)	(31,522)	(31,209)	(16,786)	(14,749)
Income tax expense (benefit)	(1,127)	(736)	(1,093)	(814)	(1,691)	(401)
Net income (loss)	(7,837)	(24,559)	(32,813)	(28,507)	(20,719)	(8,198)
Earnings per share, basic USD per share	(0.20)	(0.57)	(0.75)	(0.64)	(0.38)	(0.13)
Earnings per share, diluted USD per share	(0.20)	(0.57)	(0.75)	(0.64)	(0.38)	(0.13)
Weighted average shares, basic thousands of shares	38,819	43,359	43,573	44,656	54,435	62,232
Weighted average shares, diluted thousands of shares	38,819	43,359	43,573	44,656	54,435	62,232

Fiscal years (CTSO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	71,422	52,138	22,145	14,131	3,280	6,249
Accounts receivable	5,159	4,523	5,665	6,057	7,320	7,550
Inventory	2,674	4,766	3,462	3,680	2,733	5,281
Prepaid and other current assets	3,198	2,872	2,489	1,834	3,271	1,554
Total current assets	82,453	64,299	33,760	25,703	21,603	20,634
Property and equipment, net	2,120	5,151	10,743	10,056	9,002	7,823
Right-of-use asset	1,029	13,423	12,604	12,059	11,511	10,924
Total assets	89,950	89,519	63,232	53,261	47,372	44,182
Accounts payable	1,835	2,805	1,655	3,802	3,340	2,869
Accrued liabilities	632	1,044	851	498	—	—
Current portion of long-term debt	0	—	—	2,500	—	—
Total current liabilities	10,153	13,690	9,715	14,546	9,824	9,709
Long-term debt	0	—	5,000	2,543	13,996	16,667
Lease liability, non-current	582	13,251	13,142	12,897	12,444	11,903
Total liabilities	10,735	26,941	27,857	29,985	36,265	38,279
Accumulated deficit	(196,627)	(221,185)	(253,998)	(282,505)	(304,009)	(312,207)
Total stockholders' equity	79,216	62,578	35,375	23,275	11,107	5,903
Total liabilities and equity	89,950	89,519	63,232	53,261	47,372	44,182
Common shares outstanding (cover page) thousands of shares	43,264	43,506	43,663	54,294	≈62,500	62,700

≈ Rounded on cover: the filing states this count rounded, and it sits more than 1% off the weighted shares for the period.

Fiscal years (CTSO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(7,837)	(24,559)	(32,813)	(28,507)	(20,719)	(8,198)
Stock-based compensation	3,514	4,021	3,424	3,329	3,760	2,765
Net cash from operating activities	(5,613)	(14,006)	(28,234)	(21,655)	(14,428)	(12,377)
Purchases of property and equipment	708	3,641	6,087	538	284	164
Net cash from investing activities	(1,676)	(4,281)	(6,456)	(936)	(669)	(415)
Proceeds from issuing common stock	27,200	27,200	—	—	—	—
Proceeds from long-term debt	1,411	—	5,000	—	15,000	2,478
Repayments of long-term debt	16,411	—	—	—	5,000	—
Net cash from financing activities	66,348	715	4,960	14,474	9,331	9,309
Net change in cash	59,189	(17,596)	(29,993)	(8,217)	(5,851)	(1,993)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cytosorbents	4,413	9,633	(583)*	62.8M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
InspireMD	15,149	1,771	(10,895)*	46.5M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Edap TMS	21,542	13,203	(3,691)*	37.5M	6.5 quarters	Q2 FY26 10-QJun 30, 2026
Myomo	11,219	11,705	(1,944)*	39.6M	6.9 quarters	Q2 FY26 10-QJun 30, 2026
Orchestra BioMed Holdings	20,472	88	(19,332)*	60.1M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Monogram Technologies	12,834	not reported	(2,297)*	40.6M	5.6 quarters	Q2 FY25 10-QJun 30, 2025
Pro Dex	11,759	20,560	6,490	3.2M	—	Q1 FY27 10-QSep 30, 2026
Sensus Healthcare	15,186	2,290	(3,133)*	16.5M	4.8 quarters	Q2 FY26 10-QJun 30, 2026
Spectral AI	14,000	3,524	(4,097)*	32.2M	3.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.